Company / Cash & Equivalents
Crinetics Pharmaceuticals, Inc. Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$101.5M
FY2025
5-year range
$32.7M / $264.5M
FY2021-FY2025
Trend
-61.6%
vs FY2024
Sector context
#139 of 207
Health Care
What the data says
At $102M, Crinetics Pharmaceuticals, Inc.'s cash & equivalents ranks #139 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 9 years, ranging from $14M in FY2017 to $265M in FY2024.
Based on SEC 10-K filings.
$102M in FY2025 with a 5-year CAGR of +20.3%.
Improved from $55M to $102M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +45.9%
- 5-Year CAGR
- +20.3%
- 10-Year CAGR
- -
Sector benchmark
#139 of 207 in Health CareTop 67% of 207This company $101.5M Sector average $669.5M
▼
-84.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +20.3%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 61.6% year-over-year.
- Ranks #139 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $101.5M | -61.6% |
| FY2024 | $264.5M | +381.9% |
| FY2023 | $54.9M | +68.0% |
| FY2022 | $32.7M | -83.7% |
| FY2021 | $200.7M | +397.7% |
| FY2020 | $40.3M | -10.3% |
| FY2019 | $45.0M | +0.0% |
| FY2018 | $45.0M | +216.9% |
| FY2017 | $14.2M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026